Daiwa Securities Group Inc. boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 6,902 shares of the life sciences company’s stock after acquiring an additional 324 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Illumina were worth $2,533,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Jennison Associates LLC lifted its holdings in shares of Illumina by 4.5% in the 2nd quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock valued at $1,200,271,000 after buying an additional 185,745 shares during the period. Fred Alger Management Inc. lifted its holdings in shares of Illumina by 21.4% in the 2nd quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock valued at $217,413,000 after buying an additional 137,302 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Illumina by 5.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock valued at $168,863,000 after buying an additional 31,985 shares during the period. Millennium Management LLC lifted its holdings in shares of Illumina by 219.8% in the 2nd quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock valued at $153,318,000 after buying an additional 377,283 shares during the period. Finally, Federated Investors Inc. PA lifted its holdings in shares of Illumina by 4.1% in the 2nd quarter. Federated Investors Inc. PA now owns 512,611 shares of the life sciences company’s stock valued at $143,167,000 after buying an additional 20,324 shares during the period. 89.90% of the stock is owned by institutional investors.
In other Illumina news, EVP Marc Stapley sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $352.05, for a total transaction of $352,050.00. Following the completion of the sale, the executive vice president now directly owns 8,816 shares in the company, valued at approximately $3,103,672.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Francis A. Desouza sold 2,100 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $353.66, for a total value of $742,686.00. Following the sale, the insider now owns 75,235 shares of the company’s stock, valued at $26,607,610.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 53,464 shares of company stock valued at $17,883,331. 0.54% of the stock is owned by company insiders.
Shares of Illumina stock opened at $329.25 on Friday. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24. Illumina, Inc. has a twelve month low of $203.83 and a twelve month high of $372.61. The stock has a market capitalization of $47.44 billion, a P/E ratio of 82.31, a price-to-earnings-growth ratio of 2.40 and a beta of 1.07.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.26. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The firm had revenue of $853.00 million during the quarter, compared to analyst estimates of $825.65 million. During the same quarter in the previous year, the business earned $1.11 EPS. Illumina’s revenue for the quarter was up 19.5% compared to the same quarter last year. Analysts forecast that Illumina, Inc. will post 5.75 earnings per share for the current fiscal year.
Several brokerages have recently issued reports on ILMN. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, October 24th. Piper Jaffray Companies reissued an “overweight” rating and issued a $350.00 price objective on shares of Illumina in a report on Tuesday, July 31st. Canaccord Genuity reissued a “buy” rating and issued a $340.00 price objective (up previously from $330.00) on shares of Illumina in a report on Friday, July 27th. Barclays boosted their price objective on Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a report on Wednesday, October 24th. Finally, Citigroup boosted their price objective on Illumina from $330.00 to $345.00 and gave the company a “buy” rating in a report on Tuesday, July 31st. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $330.94.
WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/11/10/daiwa-securities-group-inc-raises-holdings-in-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: Cost of Capital
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.